Zelira Therapeutics（ZLDA.F）株式概要ゼリラ・セラピューティクス社はバイオ医薬品会社で、オーストラリアと米国において、様々な病状の治療薬としてカンナビノイドをベースとした医薬品の研究・開発・商業化に従事している。 詳細ZLDA.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析収益が 100 万ドル未満 ( A$656 )過去1年間で収益は99.3%減少しました 株式の流動性は非常に低い マイナスの株主資本 +2 さらなるリスクすべてのリスクチェックを見るZLDA.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.30333.2k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-37m2m2016201920222025202620282031Revenue AU$656.0Earnings AU$95.5AdvancedSet Fair ValueView all narrativesZelira Therapeutics Limited 競合他社RedHill BiopharmaSymbol: NasdaqCM:RDHLMarket cap: US$4.2mArtelo BiosciencesSymbol: NasdaqCM:ARTLMarket cap: US$3.7mCTT Pharmaceutical HoldingsSymbol: OTCPK:CTTHMarket cap: US$3.6mPRF TechnologiesSymbol: NasdaqCM:PRFXMarket cap: US$3.7m価格と性能株価の高値、安値、推移の概要Zelira Therapeutics過去の株価現在の株価AU$0.3052週高値AU$0.4252週安値AU$0.20ベータ0.581ヶ月の変化-14.29%3ヶ月変化n/a1年変化10.97%3年間の変化-73.91%5年間の変化-94.96%IPOからの変化-95.71%最新ニュースお知らせ • Jun 15Zelira Therapeutics Limited announced that it expects to receive $0.1 million in fundingZelira Therapeutics Limited has announced a private placement of 20% Unsecured Convertible Loan Note for gross proceeds of $100,000 on June 15, 2026. The loan note will be convertible into shares at the conversion price of $0.2812 per share. This represents an over 20% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Osagie Imasogie and who is the Non-Executive Chairman. The interest payment is 20% per annum paid monthly in cash and the maturity date is June 15, 2027. The company announced that it has obtained approval from board of directors and subject to the approval of shareholders.お知らせ • Mar 10Zelira Therapeutics Limited announced that it expects to receive AUD 0.05 million in fundingZelira Therapeutics Limited has announced a private placement of Loan Note for AUD 50,000 on March 10, 2026. The loan note will be convertible into shares at the higher of AUD 0.58 conversion price. This represents an over 14.7% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Mr Tim Slate and who is the Non-exicutive Director. The interest payment is 20% per annum paid monthly in cash and the maturity date is March 10, 2027.The transaction is subject to the approval of shareholders.お知らせ • Sep 24Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025.お知らせ • Sep 17Zelira Therapeutics Limited announced that it expects to receive $0.15 million in fundingZelira Therapeutics Limited has announced a private placement on September 16, 2025, of USD 150,000 of loan note which will become convertible into shares at the higher of USD$0.2585 and the 15-day VWAP prior Zelira electing to convert. The Loan Notes are are being executed by Oludare Odumosu and r Donna Gentile O’Donnell of f USD$100,000 and USD$50,000 respectively, on attractive terms. The interest payment is 20% per annum paid monthly in cash and the maturity date is September 16, 2026.お知らせ • Sep 12Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024.お知らせ • Jul 05Zelira Therapeutics Limited announced that it has received $1.4 million in fundingOn July 4, 2024, Zelira Therapeutics Limited closed the transaction.最新情報をもっと見るRecent updatesお知らせ • Jun 15Zelira Therapeutics Limited announced that it expects to receive $0.1 million in fundingZelira Therapeutics Limited has announced a private placement of 20% Unsecured Convertible Loan Note for gross proceeds of $100,000 on June 15, 2026. The loan note will be convertible into shares at the conversion price of $0.2812 per share. This represents an over 20% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Osagie Imasogie and who is the Non-Executive Chairman. The interest payment is 20% per annum paid monthly in cash and the maturity date is June 15, 2027. The company announced that it has obtained approval from board of directors and subject to the approval of shareholders.お知らせ • Mar 10Zelira Therapeutics Limited announced that it expects to receive AUD 0.05 million in fundingZelira Therapeutics Limited has announced a private placement of Loan Note for AUD 50,000 on March 10, 2026. The loan note will be convertible into shares at the higher of AUD 0.58 conversion price. This represents an over 14.7% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Mr Tim Slate and who is the Non-exicutive Director. The interest payment is 20% per annum paid monthly in cash and the maturity date is March 10, 2027.The transaction is subject to the approval of shareholders.お知らせ • Sep 24Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025.お知らせ • Sep 17Zelira Therapeutics Limited announced that it expects to receive $0.15 million in fundingZelira Therapeutics Limited has announced a private placement on September 16, 2025, of USD 150,000 of loan note which will become convertible into shares at the higher of USD$0.2585 and the 15-day VWAP prior Zelira electing to convert. The Loan Notes are are being executed by Oludare Odumosu and r Donna Gentile O’Donnell of f USD$100,000 and USD$50,000 respectively, on attractive terms. The interest payment is 20% per annum paid monthly in cash and the maturity date is September 16, 2026.お知らせ • Sep 12Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024.お知らせ • Jul 05Zelira Therapeutics Limited announced that it has received $1.4 million in fundingOn July 4, 2024, Zelira Therapeutics Limited closed the transaction.お知らせ • Sep 15Zelira Therapeutics Limited, Annual General Meeting, Nov 15, 2023Zelira Therapeutics Limited, Annual General Meeting, Nov 15, 2023. Agenda: To consider the re-election of Directors.お知らせ • May 31Zelira Therapeutics Limited Announces Board ChangesZelira Therapeutics Ltd. announced it has appointed Dr. Donna Gentile O'Donnell as non-executive director, effective 1 June 2023. Dr. O'Donnell served as Special Assistant to the President, Dr. Stephen K. Klasko, and is Senior Vice President for Innovation Partnerships and Programs at Thomas Jefferson University. Donna has led a diverse and successful career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organisations, universities, and life science companies, including Cephalon Pharmaceuticals. She was previously the managing director of the Eastern Technology Council for nine years. There, she played a significant role in developing and creating BioAdvance, a state entity designed to grow the life sciences industry in Southeastern Pennsylvania, as well as many other key life science initiatives. She was a special limited partner in PA Early Stage Partners. As former president of Franklin Health Trust, Dr. O'Donnell was instrumental in leading the negotiations for the merger of $50 million of the foundation's assets into the Drexel University College of Medicine. She served as Deputy Health Commissioner for Policy and Planning in the City of Philadelphia in the mid-1990s under former Mayor Ed Rendell. During that time she wrote the only successful competitive federal health care grant in the Summer of Service program, to increase the rate of immunisation for at-risk children, newborn to 2 years old and received the Clara Barton Humanitarian Award from the Southeastern Pennsylvania Chapter of the American Red Cross. In 2020, she was elected as a Fellow to the Philadelphia College of Physicians. In 2005, she was awarded Philadelphia Business Journal's Women of Distinction Award. In 2017, Gov. Tom Wolf appointed her to the Health Research Advisory Committee, which oversees the Commonwealth Universal Research Enhancement Program, or CURE. The CURE program, administered by the Pennsylvania Department of Health, advises on the distribution of 19% of the $11 billion tobacco settlement that goes to health and life-science-related research. In addition, Dr. O'Donnell served on the Women's Financial Services Network Advisory Board for PNC Bank and has served on the Regional Editorial Board of ADVANCE For Nurses. Furthermore, the company that Ms. Lisa Gray has resigned from the position of Non-Executive Director effective 31 May 2023, to focus on her other business interests and directorships. The board is wholeheartedly grateful to Ms. Gray for her significant contribution to the company as one of its founding Directors and wish her all the best with her future endeavours. Ms. Gray remains a shareholder in Zelira.お知らせ • May 22Zelira Therapeutics Limited announced that it expects to receive $22 million in fundingZelira Therapeutics Limited announced a private placement for the gross proceeds of $22 million on May 22, 2023. The company has raised $35 million in total funding till date.お知らせ • Feb 20Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive DirectorZelira Therapeutics Limited announced Mr. Greg Blake has been promoted from VP - Global Head of Commercial and Partnering to Executive Director effective 20 February 2023. Mr. Blake has been employed by Zelira since 2020. Greg brings extensive commercial and operational leadership experience in the pharmaceutical and biotech sectors both within Australia and internationally. Greg has led the strategic development and commercialisation of a number of products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a solid foundation of knowledge across marketing and the entire commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch critical pathway and commercialisation planning for both domestic and international markets. As Marketing Lead (Europe) with Mundipharma International, Greg successfully led 26 European countries through the pre-launch and launch phases for a novel pain medication.Greg has held leadership roles at large multinationals (J&J and CSL) and publicly-listed biotech start-ups.株主還元ZLDA.FUS PharmaceuticalsUS 市場7D0%1.6%-1.4%1Y11.0%40.1%16.4%株主還元を見る業界別リターン: ZLDA.F過去 1 年間で40.1 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: ZLDA.Fは、過去 1 年間で16.4 % のリターンを上げたUS市場を下回りました。価格変動Is ZLDA.F's price volatile compared to industry and market?ZLDA.F volatilityZLDA.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement9.1%Market Average Movement7.1%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: ZLDA.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のZLDA.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2003n/aOludare Odumosuzeliratx.comZelira Therapeutics Limitedはバイオ医薬品会社で、オーストラリアと米国で様々な病状の治療薬としてカンナビノイドをベースとした医薬品の研究・開発・商業化に従事している。オーストラリア、ワシントン州、ペンシルベニア州、ルイジアナ州でHOPEブランドの製剤を提供するほか、慢性不眠症治療用のカンナビノイド医薬品Zenivolを開発している。また、オーラルケア製品であるSprinJene、RAF FIVEの名称によるにきび治療製品、強化された蒸留液捕捉・溶解マトリックス技術であるZyraydiなどの市販製品も提供している。さらに、自閉症と慢性非がん性疼痛のための製品も提供している。同社は以前Zelda Therapeutics Limitedとして知られていたが、2019年12月にZelira Therapeutics Limitedに社名を変更した。Zelira Therapeutics Limitedは2003年に法人化され、オーストラリアのパースに本社を置いている。もっと見るZelira Therapeutics Limited 基礎のまとめZelira Therapeutics の収益と売上を時価総額と比較するとどうか。ZLDA.F 基礎統計学時価総額US$4.16m収益（TTM）-US$3.63m売上高(TTM)US$656.000.0xP/Sレシオ0.0xPER（株価収益率ZLDA.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ZLDA.F 損益計算書（TTM）収益AU$656.00売上原価AU$803.60k売上総利益-AU$802.94kその他の費用AU$2.82m収益-AU$3.63m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.30グロス・マージン-122,400.15%純利益率-553,029.27%有利子負債／自己資本比率-46.4%ZLDA.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 02:37終値2026/07/06 00:00収益2025/06/30年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Zelira Therapeutics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ryan HamptonHannam & Partners (Advisory) LLP
お知らせ • Jun 15Zelira Therapeutics Limited announced that it expects to receive $0.1 million in fundingZelira Therapeutics Limited has announced a private placement of 20% Unsecured Convertible Loan Note for gross proceeds of $100,000 on June 15, 2026. The loan note will be convertible into shares at the conversion price of $0.2812 per share. This represents an over 20% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Osagie Imasogie and who is the Non-Executive Chairman. The interest payment is 20% per annum paid monthly in cash and the maturity date is June 15, 2027. The company announced that it has obtained approval from board of directors and subject to the approval of shareholders.
お知らせ • Mar 10Zelira Therapeutics Limited announced that it expects to receive AUD 0.05 million in fundingZelira Therapeutics Limited has announced a private placement of Loan Note for AUD 50,000 on March 10, 2026. The loan note will be convertible into shares at the higher of AUD 0.58 conversion price. This represents an over 14.7% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Mr Tim Slate and who is the Non-exicutive Director. The interest payment is 20% per annum paid monthly in cash and the maturity date is March 10, 2027.The transaction is subject to the approval of shareholders.
お知らせ • Sep 24Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025.
お知らせ • Sep 17Zelira Therapeutics Limited announced that it expects to receive $0.15 million in fundingZelira Therapeutics Limited has announced a private placement on September 16, 2025, of USD 150,000 of loan note which will become convertible into shares at the higher of USD$0.2585 and the 15-day VWAP prior Zelira electing to convert. The Loan Notes are are being executed by Oludare Odumosu and r Donna Gentile O’Donnell of f USD$100,000 and USD$50,000 respectively, on attractive terms. The interest payment is 20% per annum paid monthly in cash and the maturity date is September 16, 2026.
お知らせ • Sep 12Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024.
お知らせ • Jul 05Zelira Therapeutics Limited announced that it has received $1.4 million in fundingOn July 4, 2024, Zelira Therapeutics Limited closed the transaction.
お知らせ • Jun 15Zelira Therapeutics Limited announced that it expects to receive $0.1 million in fundingZelira Therapeutics Limited has announced a private placement of 20% Unsecured Convertible Loan Note for gross proceeds of $100,000 on June 15, 2026. The loan note will be convertible into shares at the conversion price of $0.2812 per share. This represents an over 20% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Osagie Imasogie and who is the Non-Executive Chairman. The interest payment is 20% per annum paid monthly in cash and the maturity date is June 15, 2027. The company announced that it has obtained approval from board of directors and subject to the approval of shareholders.
お知らせ • Mar 10Zelira Therapeutics Limited announced that it expects to receive AUD 0.05 million in fundingZelira Therapeutics Limited has announced a private placement of Loan Note for AUD 50,000 on March 10, 2026. The loan note will be convertible into shares at the higher of AUD 0.58 conversion price. This represents an over 14.7% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Mr Tim Slate and who is the Non-exicutive Director. The interest payment is 20% per annum paid monthly in cash and the maturity date is March 10, 2027.The transaction is subject to the approval of shareholders.
お知らせ • Sep 24Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025.
お知らせ • Sep 17Zelira Therapeutics Limited announced that it expects to receive $0.15 million in fundingZelira Therapeutics Limited has announced a private placement on September 16, 2025, of USD 150,000 of loan note which will become convertible into shares at the higher of USD$0.2585 and the 15-day VWAP prior Zelira electing to convert. The Loan Notes are are being executed by Oludare Odumosu and r Donna Gentile O’Donnell of f USD$100,000 and USD$50,000 respectively, on attractive terms. The interest payment is 20% per annum paid monthly in cash and the maturity date is September 16, 2026.
お知らせ • Sep 12Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024.
お知らせ • Jul 05Zelira Therapeutics Limited announced that it has received $1.4 million in fundingOn July 4, 2024, Zelira Therapeutics Limited closed the transaction.
お知らせ • Sep 15Zelira Therapeutics Limited, Annual General Meeting, Nov 15, 2023Zelira Therapeutics Limited, Annual General Meeting, Nov 15, 2023. Agenda: To consider the re-election of Directors.
お知らせ • May 31Zelira Therapeutics Limited Announces Board ChangesZelira Therapeutics Ltd. announced it has appointed Dr. Donna Gentile O'Donnell as non-executive director, effective 1 June 2023. Dr. O'Donnell served as Special Assistant to the President, Dr. Stephen K. Klasko, and is Senior Vice President for Innovation Partnerships and Programs at Thomas Jefferson University. Donna has led a diverse and successful career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organisations, universities, and life science companies, including Cephalon Pharmaceuticals. She was previously the managing director of the Eastern Technology Council for nine years. There, she played a significant role in developing and creating BioAdvance, a state entity designed to grow the life sciences industry in Southeastern Pennsylvania, as well as many other key life science initiatives. She was a special limited partner in PA Early Stage Partners. As former president of Franklin Health Trust, Dr. O'Donnell was instrumental in leading the negotiations for the merger of $50 million of the foundation's assets into the Drexel University College of Medicine. She served as Deputy Health Commissioner for Policy and Planning in the City of Philadelphia in the mid-1990s under former Mayor Ed Rendell. During that time she wrote the only successful competitive federal health care grant in the Summer of Service program, to increase the rate of immunisation for at-risk children, newborn to 2 years old and received the Clara Barton Humanitarian Award from the Southeastern Pennsylvania Chapter of the American Red Cross. In 2020, she was elected as a Fellow to the Philadelphia College of Physicians. In 2005, she was awarded Philadelphia Business Journal's Women of Distinction Award. In 2017, Gov. Tom Wolf appointed her to the Health Research Advisory Committee, which oversees the Commonwealth Universal Research Enhancement Program, or CURE. The CURE program, administered by the Pennsylvania Department of Health, advises on the distribution of 19% of the $11 billion tobacco settlement that goes to health and life-science-related research. In addition, Dr. O'Donnell served on the Women's Financial Services Network Advisory Board for PNC Bank and has served on the Regional Editorial Board of ADVANCE For Nurses. Furthermore, the company that Ms. Lisa Gray has resigned from the position of Non-Executive Director effective 31 May 2023, to focus on her other business interests and directorships. The board is wholeheartedly grateful to Ms. Gray for her significant contribution to the company as one of its founding Directors and wish her all the best with her future endeavours. Ms. Gray remains a shareholder in Zelira.
お知らせ • May 22Zelira Therapeutics Limited announced that it expects to receive $22 million in fundingZelira Therapeutics Limited announced a private placement for the gross proceeds of $22 million on May 22, 2023. The company has raised $35 million in total funding till date.
お知らせ • Feb 20Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive DirectorZelira Therapeutics Limited announced Mr. Greg Blake has been promoted from VP - Global Head of Commercial and Partnering to Executive Director effective 20 February 2023. Mr. Blake has been employed by Zelira since 2020. Greg brings extensive commercial and operational leadership experience in the pharmaceutical and biotech sectors both within Australia and internationally. Greg has led the strategic development and commercialisation of a number of products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a solid foundation of knowledge across marketing and the entire commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch critical pathway and commercialisation planning for both domestic and international markets. As Marketing Lead (Europe) with Mundipharma International, Greg successfully led 26 European countries through the pre-launch and launch phases for a novel pain medication.Greg has held leadership roles at large multinationals (J&J and CSL) and publicly-listed biotech start-ups.
